49
Archived articleThis is an archived article from 2023 - please note that any content within the article may be out of date.

Market Musings 141023: The Quest for Quality

Market Musings 141023
The Quest for Quality

Summary:

  • The Benefits of Quality over the long run

  • Yes to Quality, but watch the price to pay

  • Perhaps focus on sectors outside of Tech

  • Approaches in Quality investing

Podcast this week:
Our investment strategy for October 2023

In this podcast Edmund Shing, Global Chief Investment Officer of BNP Paribas Wealth Management unveils his investment strategy for October 2023.

The Benefits of Quality over the long run

Much has been said about the advantages of investing with a quality mindset. Warren Buffett, one of the most celebrated investors in the world, is an avowed investor of quality stocks.There are many other investors who have been also celebrated for taking an explicit quality approach to investing in stocks such as Terry Smith, the founder and fund manager of Fundsmith.

First of all, what even is quality? The easiest definition of a quality stock is one which has:

  • higher than average profitability that is sustained over a long period of time, together with

  • relatively low levels of debt, or even net cash.

This can encompass a wide range of industries of course, but industries that come to mind as being dominated by quality stocks include

  • Healthcare,

  • Luxury Goods,

  • Cosmetics,

  • Premium drinks,

As well as selected monopolies and oligopolies, and technology

Essentially, we are looking for business models that can sustain higher than average profitability over a long period of time, together with reasonable or even strong growth levels. This depends in part on the quality of management, but perhaps more on the industry and the business model.

This is one reason why quality companies are often companies that have a very strong bond and image with their clients.

For instance, in the celebrated case of Costco, this food retailer tends to benefit its customers through low prices and in turn reinforces their loyalty, which ultimately reinforces the quality and growth trajectory of the company.

If we study the quality factor at work in stock markets, which can be done by using ETFs and indices that are based on the quality factor combining high profitability and low debt, you tend to find that you get better returns than for the overall stock market together with modestly lower risk.

SInce late 2016, the MSCI World Quality ETF has returned 11.6% per year on average (in euros), versus 10.7% CAGR for the broad MSCI World index, so a decent improvement over time that has resulted in a +115% return versus +104% cumulatively over this period.

Global Quality stocks have beaten the overall stock market

Bxq9R9a1O4kqFYcQP9XgNhr0wd7FbwLZ4_6CWAlswxkPx7-7CiytZTzC-zsf_vmnWUJExLWMC22_CxYaELhmkAD9pBZdV6dM2pbs7cgokBq4NvDOUwu_zHJxuDBYFfZiMIef6EvBW80301Ng1EXUiYw

Source: tradingview.com

Yes to Quality, but watch the price to pay

So comparing risk to return, the quality investment style looks very attractive for the majority of investors. Of course, the key, as with all things, is not to overpay.

The key worry I would have with the so-called quality stocks that are The Magnificent Seven mega-cap technology stocks, is not over their business models, but rather over their valuations. Currently,they trade at around 30x P/E today which is expensive by anyone's standards.

In many ways, I would prefer to look beyond technology for quality today. I believe that investors sometimes forget how short technology cycles can be, and also how new disruptive technologies can emerge to disrupt existing oligopolistic or even monopolistic companies.

I think back to the Y2K tech bubble of 2000, for instance, and the example of Cisco Systems. Back in the year 2000, Cisco was one of the biggest companies in the world, but subsequently suffered a very sharp fall in subsequent years post 2000.

Cisco and Nasdaq in 2000: Huge bubble and then bust

yg3SvnmmN2s_PkEumrYOeKHRbD0U8KcrqS9gg9JqDtt2QdHadzIbZQFONhNmh5pykt24JLurKNuwWs7fTswB3wmsHcOP_PfwqMJd3PDQju-XPHajRhvIE4ywDtm6NHjARv4WrRq1T6gpdIFtpQPKjDY

Source: tradingview.com

Clearly, its growth and monopolistic or oligopolistic positioning was not as strong as people have believed.

Additionally, perhaps the demand for IT networking equipment was perhaps more cyclical and less stable than investors believed at the time.

Equally we could talk about Nokia, which was also one of the biggest companies in the world in the year 2000. By 2006. Nokia had amassed a 44% global market share in mobile phones. But we know what happened next, the advent of the smartphone and most importantly the iPhone in 2007 for the first time effectively ended this dominant position.

Nokia today doesn't even make handsets anymore. The point here is simply that technology cycles can be shorter than you think - new disruptive technologies can emerge faster than you think.

So predicting which tech companies can maintain a long-term quality track record of high profitability is pretty difficult. From the year 2000, I would say the only mega-cap tech company really to successfully maintain such a dominant position has been Microsoft - others such as IBM have not been able to copy this feat.


Perhaps focus on sectors outside of Tech

So I would rather look to other sectors where I believe we have a better chance of predicting long term quality. Luxury goods, for instance, play on people's vanity and I believe that's something that never disappears. Luxury goods also encompass, together with premium spirits, premium pricing and profit margins on the back of reliably high quality products, a fact that is widely recognized by the end client.

Good performance from Luxury Goods and Healthcare over the long haul

tZjYzRe-csUuy3X6EKqGxdkkF0xWTQLl3uSLFprJZ667DTES9xHnYfji0D8_3b9MiwXZHBoY8x3w6dAtDYQWpxYALBPTHQIOyQWO-vX8V6zCwkrzrtagNsVotZRgfPfmZdSxxvdi5-9luU10q_lY-24

Source: tradingview.com

Healthcare similarly can be argued to have a strong quality position because of the high level of research and development plus patents that exist within the industry, particularly for pharmaceuticals. These “moats” allow companies to build up strong positions of high profitability once they own blockbuster drugs, which enjoy patent protection for many years.

The best current example of this clearly is Novo Nordisk, the Danish company which produces diabetes treatments, notably insulin, but now has seen explosive growth thanks to its diabetes treatment Wegovy, which is now marketed for weight loss as Ozempic and is enjoying fabulous growth in what is a very large total addressable market, potentially.

But there are many other areas of quality that we should examine. The notion of pricing power is important, as is the notion of an oligopolistic position in a given market. Stock Exchange operators such as LSEG (London Stock Exchange) fulfil this, as do financial service companies that produce indices such as MSCI or Standard & Poors for instance. These companies have demonstrated high profitability over many years due to the strong brand names that they enjoy, which gives them a form of oligopolistic positioning within the fast-growing area of indices, which underlie exchange traded funds.

Approaches in Quality investing

There are different ways to invest in quality. Firstly, you can pick your own stocks and naturally, this would lead you to focus on a number of companies in a number of sectors, such as perhaps technology, but more importantly luxury goods, healthcare, premium spirits, stock exchanges, index providers, and so on.

Or you could simply invest in a fund or exchange traded fund that invests explicitly in quality stocks. Many people for instance like to invest in the FundSmith range of funds for this approach. Although one should note that Fundsmith has a very explicit bias currently towards large cap US tech stocks, which of course has served it well, but has a very particular bias which you may or may not want to take.

Otherwise, there are quality factor exchange traded funds from iShares, Amundi and xTrackers that track world or European quality factor indices. These ETFs invest in quality on a quantitative basis, using the factors of high profitability such as high return on capital and low debt or net cash.

Both of these approaches have been relatively successful over the medium term over the last few years. Typically, if we look at a quality factor ETF based on an underlying index, you tend to find in Europe or globally that these ETFs tend to slightly outperform during bull markets. More importantly, they also tend to lose a little bit less than the overall stock market in percentage terms during bear markets. Hence this is why when you take a long period including both bull and bear markets together, you tend to find outperformance of these quality factor ETFs and indices over the overall stock market

Hence, for most investors who want to sleep soundly at night, but do want to invest in the stock market, I would argue that investing explicitly in either a quality factor ETF or a quality based stock fund like Fundsmith makes a lot of sense, because of these better than average risk return characteristics.

It won’t protect you clearly from negative performance during a bear market. But it should help to cushion the blow somewhat; and note that in the following bull market, you should regain your losses even quicker than for the stock market overall.

Today you have plenty of choice in quality funds. Global quality funds typically have a very big US bias right now, as is typical indeed for the overall stock market, with the US representing more than two thirds of the MSCI World Index at the moment.

European quality funds clearly have a bigger bias to sectors such as branded goods and healthcare rather than technology, as is the case with the global funds but are still relatively attractive. Because not only do you invest in quality, but you also invest in what I consider to be a relatively cheap stock market versus for instance, the US right now.

In conclusion, I would urge you all to invest in quality either through your stock picking by focusing on companies with sustainably high profitability in terms of operating margin and return on capital, but also with relatively low debt or net cash, which should underline the fact that quality companies also tend to be strong and reliable. free cash flow generators over time.

One twist on the quality factor is also to invest in dividend quality and dividend growth. And this can also be done by funds and ETFs. This ensures a steady level of income, but generally an income that can also grow steadily over time.

Have a great week,

Edmund

Disclaimer

This is not financial advice. Our content is intended to be used and must be used for information and education purposes only. Please read our disclaimer and terms and conditions to understand our obligations.

17 comments


Avatar for Pat W

Thanks, really interesting . I love the last paragraph. 

0
Avatar for Cuddlesticks

Thanks Edmund. I’m not sure that large healthcare are less exposed to ‘technology cycles’ than tech stocks. You only have to look at the relative performances of Big Pharma (e.g. GSK, AZ, Novartis, Pfizer, Eli Lily, JNJ) to see the challenges managing patent cliffs. It seems more feast and famine and, these days, the success of biotech acquisition strategies to me.

2
Avatar for Rusty2

Pfizer (NYQ:PFE) are not doing at all well but Novo Nordisk A/S (CPH:NOVO B) are still soaring.

Fundsmith have made some poor decisions lately, PayPal Holdings (NSQ:PYPL) and Adobe (NSQ:ADBE) are just 2 of them. LVMH Moet Hennessy Louis Vuitton SE (EPA:MC) are not exactly going so well.

0
Avatar for BnB

LVMH Moet Hennessy Louis Vuitton SE (EPA:MC) are not exactly going so well.

Precisely when you should be buying. (Hopefully) short term headwinds making the share as cheap as it has been for years. 

0
Avatar for Monty Carlo

The real Fundsmith shocker is Estee Lauder Companies (NYQ:EL)

0
Avatar for BnB

The real Fundsmith shocker is Estee Lauder Companies (NYQ:EL)

I agree and I’ve seen all my gains since 2018 wiped out. To be clear, it is short term very annoying. But does it matter if on a long term basis the company eventually recovers equilibrium? The principle of quality investing is to ignore the short term swings that traders exploit and just own the best companies - who will all endure tough conditions at some point. Only if the market for their product, or the quality of management has fundamentally changed, should you sell. That’s why Fundsmith sold PayPal but not EL.

0
Avatar for Rusty2

They sold Adobe (NSQ:ADBE) for 20% loss, since then it has gone up around 60%. Also sold Intuit (NSQ:INTU) last December, it has since bone up 50%. Has Terry Smith lost his touch?  
Thought they had sold EL now?

Yes sold EL in August, bought Marriott International (NSQ:MAR).

0
Avatar for BnB

You’re correct. My bad. Perhaps he’s unhappy with management there too. Can’t say I’m thrilled :-]

0
Avatar for Monty Carlo

Yes, Fundsmith has sold Estee Lauder Companies (NYQ:EL) , but just look at what the valuation metrics were while it was in the fund. To be fair it was a secondary holding to L'oreal SA (EPA:OR) .

You can trace the origins of Terry/Fund Smith's process back to the days of Collins Stewart and their Quest system. I don't want to fall foul of the lawyers so I will ask readers to draw their own conclusions on the legal dispute between Holt Value Associates (acquired by CSFB) and Collins Stewart. I've used both systems and both adopt a CFROI (Cashflow Return On Investment) approach. They are useful systems, but in the end you still need to make huge assumptions on terminal growth rates etc - like a DCF you have to input assumptions for future years, well beyond this year & next which is about as far out as City analysts will publish their models. Small changes in assumptions can result in huge changes in present value.

Problem is, it isn't difficult to identify many of the holdings in Fundsmith - a Stocko screen for high ROCE will flag up many of them, and they tend to trade at a premium valuation. It then becomes a question of whether the growth will come through over a multi-year horizon to justify the high valuation - that is very difficult to judge, and requires more skills than simple financial analysis (such as "predicting the future").

There is more nuance in the "Owners Manual" (which is about as coherent as any other fund manager process), but one of Terry Smith's marketing straplines is "Don't pay too much".

If his preferred stocks are trading at expensive valuations, what does Fundsmith do about inflows into the fund? Pay too much?

Answers on a postcard to Terence Smith.

3
Avatar for BnB

If there’s one area where Fundsmith is less reliable in its selections, it would be software. In a rare case of me outperforming a superstar fund manager, I added to Adobe and bought Intuit just as he was selling. But this thread is about quality investing in general, of which I’m an adherent, not Terry Smith. And Edmund did not instruct readers to buy Smith’s funds.

I try to keep it simple. While always checking first that ROCE, margins and debt are clear of my thresholds, I simply ask myself: “do I want to own this company long term for its quality products, defensive moat and exposure to secular growth. And would I be comfortable owning it through a difficult period economically or in bear markets”. 

4
Avatar for Monty Carlo

Funnily enough I am cautious on following Fundsmith into holdings - the fund is probably big enough to inflate the price as he buys in and depress a share price if he turns a seller.

In looking for companies with similar characteristics that are not current Fundsmith holdings I've looked at:

Fair Isaac (NYQ:FICO)
WW Grainger (NYQ:GWW)
Mcdonald's (NYQ:MCD)
S&P Global (NYQ:SPGI)
Colgate-Palmolive Co (NYQ:CL)
Rockwell Automation (NYQ:ROK)

Of couse these have some overlap with stocks that are in Fundsmith - Verisk Analytics (NSQ:VRSK) , PepsiCo (NSQ:PEP) , MSCI (NYQ:MSCI) , Procter & Gamble Co (NYQ:PG)


I also keep an eye on the the lower-rated semiconductor companies which Fundsmith avoids due to cyclicality/capital intensity:
Texas Instruments (NSQ:TXN) , Analog Devices (NSQ:ADI)

And then Intel (NSQ:INTC) is a fascinating recovery play where you could lose a few fingers. People forget Intel makes some passable graphics cards & is not completely out of the game.

0
Avatar for BnB

Interesting choices with only one crossover to my portfolio. That could be a good sign :-)

I would be wary that FICO could be disintermediated by AI, although the market has no such concerns. When Upstart the AI-based credit scoring business was flying high on the market there were ample reports that its software was outperforming FICO. Since then, investors have turned their attention to the new entrant's weak balance sheet. Equally, FICO could embrace AI to dramatically cut costs. 

McDonalds is at a low valuation next to history but is depressed by fears over Wegovy and the fall in consumer staples over bond yields. Are the weight-loss drug concerns justified? If not, good entry today. 

Rockwell is cyclical to an abnormal level next to automation competitors. I prefer and own large (for me) stakes in Schneider Electric and Eaton. Keyence is even stronger and very depressed relative to history. Can you handle a PER of 35x in return for EBITDA margins in excess of 50%? Now that's quality! No comment on Colgate, but Grainger is a beast!

My pick of your six would be S&P Global. Just look at the very long term record of shareholder value creation, huge moat, and some of the best operating numbers you'll see anywhere. Not expensive relative to historical norms today. I have a large and enduring position.

3
Avatar for Monty Carlo

I was in there with you on INTU but I'm afraid I'm not such a fan of Adobe (NSQ:ADBE) .

I am a keen photographer, and certainly amongst the amateur/semi-pro market they have quite a resentful clientele since they forced everyone across to their Creative Cloud subscription model and many people are looking for alternatives.

I find Photoshop does more than I need, and I can make do with open source GIMP when I need layers. For RAW files I prefer to use Canon's own DPP. I hear good things about Capture One.

Difficult to tell whether AI is friend or foe for Adobe - I can see some of the AI image generators taking a share of the pie at the low end where people are happy with "good enough".

Then you have the incursion of smartphones with their built in software tricks.

As for pdfs, I edit them for free using LibreOffice....

So I don't really have much faith in the "moat", although I concede they are dominant in the commercial space.

2
Avatar for Rusty2

I'm a keen photographer also. Photoshop, I don't use the cloud version, just CS6 which is on a disk. I also use Topaz which is good for noise, B&W and a few other things. Nik Efex is available free, just started to use that. If starting now, I doubt I would subscribing to Photoshop.

I did holdAdobe (NSQ:ADBE) but sold out now, thought Fundsmith would have held on to it for longer, think was at a bad time after big losses on PayPal Holdings (NSQ:PYPL) etc.

0
Avatar for Cuddlesticks

My point was about the sustainability of the competitive moat i.e. it doesn't last that long in pharma.

0
Avatar for AdamPeck13

Thanks Edmund, very interesting.

0
Avatar for Silver Moon

Good day Edmund, we had our first frost this morning but my porfolios have been frosted up for a long time now.  From now on, after a couple of day taking a hard look at the 120-odd companies in my portfolios I intend to concentrate on QV among them, Value not being so much as P/E but that according to Stocko.  With an eye on dividends too, I realise that if a high dividend drops then the share price must have risen or else something must be wrong.   I'm unwilling to look outside those portfolios as those within are quite enought be going on with and whittling down.  I also remain within the UK listings as I'm insufficiently experienced to add other countries to my ii subscription.

3
Get the free newsletter